Xencor Shares Rise 16% Following Positive Early Clinical Data for XmAb819
Shares of Xencor (XNCR) surged nearly 16% on Monday following the announcement of encouraging early-stage clinical data for its investigational cancer treatment, XmAb819. The company is a clinical-stage biopharmaceutical firm specializing in engineered antibody therapeutics designed to treat cancer and autoimmune diseases. The positive data release has provided significant momentum for the stock, reflecting investor optimism regarding the potential efficacy of Xencor's therapeutic pipeline. This development marks a key milestone in the clinical progression of its oncology assets.
Tickers: $XNCR
Topics: biopharmaceuticals clinical trial data oncology stock price movement